Kalaris Therapeutics Inc share price logo

Kalaris Therapeutics Inc Share Price

NASDAQ: KLRS

Small Cap

$10.45

-0.01

(-0.10%)

Live

as on

Kalaris Therapeutics Inc Stock Performance

as on March 3, 2026 at 6:08 am IST

  • Day's Low

    Day's High

    $10.10
    $10.69
    downward going graph

    3.35%

    Downside

    2.30%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $2.14
    $12.90
    downward going graph

    79.52%

    Downside

    23.44%

    Upside

    downward going graph

Kalaris Therapeutics Inc share price movements today

Previous Close
$10.46
Open
$10.19
Volume
73.2K
Day's Low - High
$10.10 - $10.69
52 Week Low - High
$2.14 - $12.90

Kalaris Therapeutics Inc Historical Returns

1 Month Return
+ 14.82 %
3 Month Return
+ 91.22 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Kalaris Therapeutics Inc Stock Fundamentals & Key Indicators

Check Kalaris Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$195.6M

EPS (TTM)

-3.6967

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

0.00%

Kalaris Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Kalaris Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Kalaris Therapeutics Inc image
Kalaris Therapeutics Inc
NA$195.6MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$44.2B118.44%142.888.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$126.2B134.29%32.4732.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$35.1BNA621.555.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$82.6B71.85%18.8331.41%

Kalaris Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Kalaris Therapeutics Inc Stock has decreased by -39% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-39% versus previous 30 day period

Kalaris Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
-
-
-
Operating Income
-3
-2
-4
-37
-10
-12
-12
EBITDA
-3
-3
-5
-37
-8
-11
-11
Interest Expense
0
0
0
0
1
-
-
Depreciation
-
-
-
-
-
-
-
Income Before Tax
-3
-3
-5
-38
-10
-11
-11
Income Tax Expense
-
-
-
-
-
-
-
Net Income
-3
-3
-5
-38
-10
-11
-11
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Kalaris Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2022
Dec 2023
Total Revenue
1
0
-
-
Gross Profit
-
-
-
-
Operating Income
-3
-26
-14
-13
EBITDA
-2
-23
-15
-14
Interest Expense
-
-
0
0
Depreciation
-
-
-
-
Income Before Tax
-2
-23
-15
-14
Income Tax Expense
-
-
-
-
Net Income
-2
-23
-15
-14
Net Profit Margin
-214.10%
-14447.88%
0.00%
0.00%

Kalaris Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Mar 2025
Jun 2025
Sep 2025
Net Income
-45
-44
-3
-3
-5
-38
-10
-11
-11
Operating Cash Flow
-27
-34
-4
-4
-3
-4
-7
-14
-11
Investing Cash Flow
37
-66
-
-
-
-
-
-
-34
Financing Cash Flow
70
-
6
6
4
0
107
2
-
Change in Cash
81
-101
2
2
1
12
99
-12
-46

Kalaris Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-23
-69
-171
-15
-14
-58
Operating Cash Flow
-20
-60
-106
-9
-14
-67
Investing Cash Flow
-64
-169
185
-
-
95
Financing Cash Flow
120
291
0
12
14
0
Change in Cash
36
61
79
3
0
28

Insights on Kalaris Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, KLRS stock has moved up by 91.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 34.9% return, outperforming this stock by 28.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 71.2% return, outperforming this stock by 163.7%

About Kalaris Therapeutics Inc

Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
OrganisationKalaris Therapeutics Inc
Headquarters628 Middlefield Road, Palo Alto, CA, United States, 94301
CEOMr. Andrew Oxtoby
E-voting on sharesClick here to vote

Key Management of Kalaris Therapeutics Inc

Name

Title

Dr. Srinivas Akkaraju M.D., Ph.D.

Director & Co-Founder

Dr. Michael Philip Dybbs Ph.D.

Director & Co-Founder

Ms. Kristine Curtiss

Senior Vice President of Clinical

Dr. Jill E. Porter Ph.D.

Senior Vice President of CMC

Mr. Andrew Oxtoby

President, CEO & Director

Dr. Napoleone Ferrara M.D.

Independent Director & Co-Founder

Mr. Matthew Gall M.B.A.

CFO & Treasurer

Mr. Brett R. Hagen

Chief Accounting Officer

Dr. Matthew Feinsod M.D.

Chief Medical Officer

FAQs

What is Kalaris Therapeutics Inc share price today?

Kalaris Therapeutics Inc share price today is $10.45 as on . Kalaris Therapeutics Inc share today touched a day high of $10.69 and a low of $10.1.

What is the 52 week high and 52 week low for Kalaris Therapeutics Inc share?

Kalaris Therapeutics Inc share touched a 52 week high of $12.9 on and a 52 week low of $2.14 on . Kalaris Therapeutics Inc stock price today i.e. is trending at $10.45,which is 18.99% down from its 52 week high and 388.32% up from its 52 week low.

What is Kalaris Therapeutics Inc's market capitalisation today?

Kalaris Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Kalaris Therapeutics Inc Stock (KLRS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Kalaris Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Kalaris Therapeutics Inc Shares that will get you 0.1435 shares as per Kalaris Therapeutics Inc share price of $10.45 per share as on March 3, 2026 at 12:38 am IST.

What is the minimum amount required to buy Kalaris Therapeutics Inc Stock (KLRS) from India?

Indian investors can start investing in Kalaris Therapeutics Inc (KLRS) shares with as little as ₹91.474 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹914.74 in Kalaris Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Kalaris Therapeutics Inc share’s latest price of $10.45 as on March 3, 2026 at 12:38 am IST, you will get 0.9569 shares of Kalaris Therapeutics Inc. Learn more about fractional shares .